NCT02194465

A Study of LY2623091 in Participants With High Blood Pressure

A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 304 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.

Conditions

• Primary Hypertension

Interventions

Type	Name	Description
DRUG	LY2623091	Administered orally
DRUG	Tadalafil	Administered orally
DRUG	Spironolactone	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2014-07-18
• Last updated: 2020-06-26
• Results posted: 2020-06-26

Locations

43 sites across 3 countries: United States, Canada, Puerto Rico